Vitamin D pp 207-216 | Cite as

Noncalcemic Actions of 1,25-Dihydroxyvitamin D3 and Clinical Implications

  • Michael F. Holick
Part of the Nutrition and Health book series (NH)


Vitamin D is synonymous with bone health and calcium metabolism. It is the biologically active vitamin D metabolite, 1, 25-dihydrovitamin D [1, 25(OH)2D; D without a subscript represents either D2 or D3] that is responsible for maintaining serum calcium levels in the normal range by increasing the efficiency of intestinal calcium absorption. When dietary calcium absorption is inadequate to satisfy the body’s requirement, then 1, 25(OH)2D mobilizes stem cells and induces them to become mature osteoclasts, which in turn mobilize calcium stores from bone to maintain serum calcium in a physiologically acceptable range (1–3).


Maintain Serum Calcium Level Dietary Calcium Absorption Chick Embryo Skeletal Muscle 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Holick MF. Vitamin D: photobiology, metabolism, mechanism of action, and clinical application. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 3rd ed. Favus MJ, ed. Philadelphia: Lippincott-Raven, 1996; 74–81.Google Scholar
  2. 2.
    Holick MF. Vitamin D. photobiology, metabolism, and clinical applications. In: Endocrinology, 3rd ed. DeGroot L, et al., eds. Philadelphia: WB Saunders, 1995; 990–1013.Google Scholar
  3. 3.
    Holick MF, Krane S, Potts JR Jr. Calcium, phosphorus, and and bone metabolism: calcium-regulating hormones. In: Harrison’s Principles of Internal Medicine, 13th ed. Isselbacher KJ, Braunwald E, Wilson JD, et al., eds. New York: McGraw-Hill, 1994; 2137–2151.Google Scholar
  4. 4.
    Stumpf WE, Sar M, Reid FA, et al. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979; 206: 1188–1190.PubMedCrossRefGoogle Scholar
  5. 5.
    Kim YS, Stumpf WE, Clark SA, Sar M, DeLuca HF. Target cells for 1,25-dihyroxyvitamin D3 in developing rat incisor teeth. J Dent Res 1983; 62: 58, 59.Google Scholar
  6. 6.
    Stumpf WE, Sar M, Narbaitz R, Huang S, DeLuca HF. Autoradiographic localization of 1,25, dihydroxyvitamin D3 in rat placenta and yolk sac. Horm Res 1983; 18: 215–220.PubMedCrossRefGoogle Scholar
  7. 7.
    Abe E, Miyaura C, Sakagami H, et al. Differentiation of rat myc leukemia cells induced by 1,25dihydroxyvitamin D3. Proc Natl Acad Sci USA 1981; 78: 4990–4994.PubMedCrossRefGoogle Scholar
  8. 8.
    Eisman JA, Suva LJ, Sher E, Pearce PJ, Funder JW, Martin TJ. Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer. Cancer Res 1981; 41: 5121–5124.PubMedGoogle Scholar
  9. 9.
    Colston K, Colston MJ, Feldman D. 1,25-Dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981; 108: 1083–1086.PubMedCrossRefGoogle Scholar
  10. 10.
    Bikle DD, Pillai S, Gee E. Squamous carcinoma cell lines produce 1,25-dihydroxyvitamin D, but fail to respond to its prodifferentiating effect. J Invest Dermatol 1991; 97: 435–441.PubMedCrossRefGoogle Scholar
  11. 11.
    Halline AG, Davidson NO, Skarosi SF, Sitrin MD, Tietze C, Alpers DH, Brasitus TA. Effects of 1,25dihydroxyvitamin D3 on proliferation and differentiation of Caco-2 cells. Endocrinology 1994; 134: 1710–1717.PubMedCrossRefGoogle Scholar
  12. 12.
    Manolagas SC, Provvedine DM, Murray EJ, Tsoukas CD, Deftos LJ. The antiproliferative effect of calcitriol on human peripheral blood mononuclear cells. J Clin Endocrinol Metab 1986; 63: 394–400.PubMedCrossRefGoogle Scholar
  13. 13.
    Provvedine DM, Tsoukaas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983; 221: 1181.CrossRefGoogle Scholar
  14. 14.
    Tsoukas CD, Provvedine DM, Manolagas SC. 1,25-Dihydroxyvitamin D3, a novel immuno-regulatory hormone. Science 1984; 221: 1438–1440.CrossRefGoogle Scholar
  15. 15.
    Provvedine DM, Tsoukas CD, Deftos LJ, Manolagas SC. l a,25-Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. J Immunol 1986; 136: 2734–2739.Google Scholar
  16. 16.
    Bhalla AK, Clemens T, Amento E, Holick MF, Krane SM. Specific high-affinity receptors for 1,25dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 1983; 57: 1308–1310.PubMedCrossRefGoogle Scholar
  17. 17.
    Kuribayashi T, Tanaka H, Abe E, Suda T. Functional defect of variant clones of a human myeloid leukemia cell line (HL-60) resistant to 1a,25-dihydoxyvitamin D3. Endocrinology 1983; 113: 1992–1998.PubMedCrossRefGoogle Scholar
  18. 18.
    Honma Y, Hozumi M, Abe E, Konno K, Fukushima M, Hata S, Nishii Y, DeLuca HF. 1 a,25- Dihydroxyvitamin D3 and la-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 1982; 80: 201–204.CrossRefGoogle Scholar
  19. 19.
    Eisman JA. 1,25-Dihydroxyvitamin D3 receptor and role of 1,25-dihydroxyvitamin D3 in human cancer cells in vitamin D. In: Vitamin D. Basic and Clinical Aspects. Kumar R, ed. Boston: Martinus Nijhoff, 1984; 365–382.Google Scholar
  20. 20.
    Stumpf WE, Clark SA, Sar M, DeLuca HF. Topographical and developmental studies on target sites of 1, 25(OH)2-vitamin D3 in skin. Cell Tissue Res 1984; 238: 489–496.Google Scholar
  21. 21.
    Clemens TL, Adams JS, Horiuchi N, et al. Interaction of 1,25-dihydroxyvitamin D3 with keratinocytes and fibroblasts from skin of normal subjects and a subject with vitamin D-dependent rickets, type II. J Clin Endocrinol Metab 1983; 56: 824–830.PubMedCrossRefGoogle Scholar
  22. 22.
    Smith EL, Walworth ND, Holick MF. Effect of 1,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986; 86: 709–714.PubMedCrossRefGoogle Scholar
  23. 23.
    Bikle DD, Gee E, Pillai S. Regulation of keratinocyte growth, differentiation, and vitamin D metabolism by analogs of 1,25-dihydroxyvitamin D. J Invest Dermatol 1993; 101: 713–718.PubMedCrossRefGoogle Scholar
  24. 24.
    Mansur CP, Gordon PR, Ray S, Holick MF, Gilchrest BA. Vitamin D, its precursors, and metabolites do not affect melanization of cultured human melanocytes. J Invest Dermatol 1988; 91: 16–21.PubMedCrossRefGoogle Scholar
  25. 25.
    Milde P, Hauser U, Simon T, Mall G, Ernst V, Haussler MR, Frosch P, Rauterberg E. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol 1991; 97: 230–239.PubMedCrossRefGoogle Scholar
  26. 26.
    Akerstrom VL, Walters M. Physiological effects of 1,25-dihydroxyvitamin D3 in TM4 sertoli cell line. Am J Physiol 1992; 262: E884 - E890.PubMedGoogle Scholar
  27. 27.
    Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952–1960.PubMedCrossRefGoogle Scholar
  28. 28.
    Boland R, Norman A, Ritz E, Hausselbach W. Presence of 1,25-dihydroxyvitamin D3 receptor in chick skeletal muscle myoblasts. Biochem Biophys Res Commun 1985; 128: 305–311.PubMedCrossRefGoogle Scholar
  29. 29.
    Walters MR, Ilenchuk TT, Claycomb WC. 1,25-Dihydroxyvitamin D3 stimulates 45Ca2+ uptake by cultured adult rat ventricular cardiac muscle cells. J Biol Chem 1987; 262: 2536–2541.PubMedGoogle Scholar
  30. 30.
    Weishaar RE, Simpson RU. The involvement of the endocrine system in regulating cardiovascular function: emphasis on vitamin D3. Endocr Rev 1989; 10: 1–15.CrossRefGoogle Scholar
  31. 31.
    Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990; 86: 1313–1319.PubMedCrossRefGoogle Scholar
  32. 32.
    Fukuda N, Tanaka H, Tominaga R, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436–1443.PubMedCrossRefGoogle Scholar
  33. 33.
    Lemire JM, Adams JS, Sakai R, Jordan SC. la,25-Dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 1984; 74: 657–661.PubMedCrossRefGoogle Scholar
  34. 34.
    Branisteanu DD, Mathieu C, Cateels K, Bouillon R. Combination of vitamin D analogs and immuno suppressants. Clin Immunother 1996; 6: 1–14.CrossRefGoogle Scholar
  35. 35.
    Lorente F, Fontan G, Jara P, Casas C, Garcia-Rodriguez MC, Ojeda JA. Defective neutrophil motility in hypovitaminosis D rickets. Acta Paediatr Scand 1976; 65: 695–699.PubMedGoogle Scholar
  36. 36.
    Holick MF. Noncalcemic actions of 1,25-dihydroxyvitamin D3 and clinical applications. Bone 1995; 17 (Suppl): 107S - 111S.PubMedCrossRefGoogle Scholar
  37. 37.
    Koren R, Ravid A, Liberman UA, Hochberg Z, Weisman Y, Novogrodsky A. Defective binding and function of 1,25-dihydroxyvitamin D3 receptors in peripheral mononuclear cells of patients with end-organ resistance to 1,25-dihydroxyvitamin D. J Clin Invest 1985; 76: 2012–2015.PubMedCrossRefGoogle Scholar
  38. 38.
    Binderup L. Immunological properties of vitamin D analogues and metabolites. Biochem Pharmacol 1992; 43: 1885–1892.PubMedCrossRefGoogle Scholar
  39. 39.
    Kitajima I, Maruyama I, Matsubara H, Osame M, Igata A. Immune dysfunction in hypophosphatemic vitamin D resistant rickets: immunoregulatory reaction of la-(OH) vitamin D3. Clin Immunol Immunopathol 1989; 53: 24–31.PubMedCrossRefGoogle Scholar
  40. 40.
    Holick MF. Photobiology and noncalcemic actions of vitamin D. In. Principles of Bone Biology. Raisz LG, Rodan GA, Bilezikian JP, eds. San Diego: Academic Press, 1996; 447–460.Google Scholar
  41. 41.
    Weintroub S, Winter CC, Wahl SM, Wahl LM. Effect of vitamin D deficiency on macrophage and lymphocyte function in the rat. Calcif Tissue Int 1989; 44: 125–130.CrossRefGoogle Scholar
  42. 42.
    Suda T, Abe E, Miyaura C, Tanaka H, Shiina Y, Kuribayashi T. Vitamin D and its effects on myeloid leukemia cells. In: Vitamin D, Basic and Clinical Aspects. Kumar R, ed. Boston: Martinus Nijhoff, 1984; 365–382.Google Scholar
  43. 43.
    Amento EP. Vitamin D and the immune system. Steroids 1987; 49: 55–72.PubMedCrossRefGoogle Scholar
  44. 44.
    Fournier C, Gepner P, Sadouk MB, Charreire J. In vivo beneficial effects of cyclosporin A and 1,25dihydrovitamin D3 on the induction of experimental autoimmune thyroiditis. Immunol Immunopathol 1990; 54: 53–63.CrossRefGoogle Scholar
  45. 45.
    Lemire JM, Archer DC. 1,25-Dihydrovitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991; 87: 1103–1107.PubMedCrossRefGoogle Scholar
  46. Chiocchia G, Boissier MC, Pamphile R, Fournier C. Enhancement of skin allograft survival in mice by association of 1-alpha-hydroxyvitamin D3 to infratherapeutic does of cyclosporin A. In: Vitamin D. Gene Regulation, Structure-Function Analysis and Clinical Application. Norman AW, Bouillon R, Thomassett M, eds. Berlin: Walter de Gruyter, 1991; 514–515.Google Scholar
  47. 47.
    Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994; 37:552–558,.Google Scholar
  48. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. PSEBM 1997; 216:21–27.Google Scholar
  49. 49.
    Koeffler HP, Hirjik J, Iti L, the Southern California Leukemia Group. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985; 69: 1399–1407.PubMedGoogle Scholar
  50. 50.
    Arlet P, Nicodeme R, Adoue D, Larregain-Fournier D, Delsol G, Le Tallec Y. Clinical evidence for 1,25-dydroxycholecalciferol action in myelofibrosis. Lancet 1984; 1: 1013, 1014.Google Scholar
  51. 51.
    Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995; 16: 200–257.PubMedGoogle Scholar
  52. 52.
    Perez A, Chen TC, Turner A, Raab R, Bhawan J, Poche P, Holick MF. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134: 238–246.PubMedCrossRefGoogle Scholar
  53. 53.
    Kragballe K. Treatment of psoriasis by the topical application of the novel vitamin D3 analogue MC 903. Arch Dermatol 1989; 125: 1647–1652.PubMedCrossRefGoogle Scholar
  54. 54.
    Kato T, Rokugo M, Terui T, Tagami H. Successful treatment of psoriasis with topical application of active vitamin D3 analogue, la,24-dihydroxycholecalciferol. Br J Dermatol 1986; 115: 431–433.PubMedCrossRefGoogle Scholar
  55. 55.
    Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134: 1070–1078.PubMedCrossRefGoogle Scholar
  56. 56.
    Huckins D, Felson DT, Holick MF. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study. Arthritis Rheum 1990; 33: 1723–1727.PubMedCrossRefGoogle Scholar
  57. 57.
    Jimenez JJ, Yunis AA. Protection from chemotherapy-induced alopecia by 1,25-dihydroxyvitamin D3. Cancer Res 1992; 52: 5123–5125.PubMedGoogle Scholar
  58. 58.
    Holick MF, Chen ML, Kong XF, Sanan DK. Clinical uses for calciotropic hormones 1,25-dihydroxyvitamin D3 and parathyroid hormone-related peptide in dermatology: a new perspective. J Invest Dermatol 1996; 1: 1–19.Google Scholar
  59. 59.
    Suda T, Abe E, Miyaura C, et al. Vitamin D in the differentiation of myeloid leukemia cells. In: Vitamin D: Basic and Clinical Aspects. Kumar R, ed. The Hague: Nijhoff, 1984; 343–363.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Michael F. Holick

There are no affiliations available

Personalised recommendations